Intervalolibre

Ginecología oncológica y mastología en tiempo libre. Gynecologic Oncology and Breast Cancer information in free time.

[Intervalolibre @intervalolibre]

Foro virtual " Citorreducción secundaria en cáncer de ovario epitelial platino sensible".

https://t.co/xGw2vtXb3Q

#cancerdeovario #intervalolibre #ginecologíaoncológica

[Emad Mikhail @Mikhail_MIGS]

@Baselrefky I am sorry to hear that. Get well soon. You are putting GYN ONC in Egypt on the map.

[@GynOncJnls @gynoncjnls]

🇧🇷 Case report: Symptomatic uterine leiomyomatosis with intracaval and intracardiac invasion‼️@SGO_org @IGCSociety @ESGO_society @OncoAlert @acog @AHAScience @STS_CTsurgery https://t.co/nsZCZNSLnl

[@GynOncJnls @gynoncjnls]

Routine SLN biopsy for endometrial intraepithelial neoplasia: A pragmatic approach or over-treatment? @RobinsonRossiGO @DukeMedSchool @dukeobgyn @SGO_org @IGCSociety @ESGO_society @OncoAlert https://t.co/U5a8CPe3iU

[Peter WT Pisters, MD @ppisters]

Reflecting on the remarkable impact of our @MDAndersonNews teams as highlighted in this article. Proud of our teammates’ collective efforts to advance our strategic Breakthroughs theme and our research mission for the benefit of our patients. https://t.co/uWbN3UPV1b #EndCancer

[Luis Moreno Sánchez @radioncoluis]

Surgical Management of the Axilla for Breast Cancer.
https://t.co/MneqAf9odZ

[AJOG @AJOG_thegray]

AJOG Systematic Review: Risk of endometrial cancer in asymptomatic postmenopausal women in relation to ultrasonographic endometrial thickness: systematic review and diagnostic test accuracy meta-analysis https://t.co/uxPx8Jr160

[Erika Hamilton, MD, FASCO @ErikaHamilton9]

Honor to be the editor for this edition of @JWatch .

Some fantastic pieces in here by @MeganTesch @AnnPartridgeMD @LoiblSibylle @MichaelGnant @hoperugo and others....all #bcsm!

@SarahCannonDocs @OncoAlert

[ESTRO @ESTRO_RT]

#ESTROnewsletter Partial breast irradiation versus whole Breast irradiation for early breast cancer patients in a randomised phase III trial: The Danish breast cancer group partial breast irradiation trial https://t.co/myBbgk6xay

[Thales P. Batista, MD, PhD @BatistaTP]

#SLB in open #surgery for gynecological malignancies, via ⁦@IJGConline⁩ . I will record a video article like this using our developing @eLightICG⁩…⁦@glaucobaiocchi⁩ ⁦@sbco_oficial⁩ ⁦@br_gynoncgroup⁩ ⁦⁩ ⁦@isfgs⁩ https://t.co/V4zvOKteBr

[Harvard Medical School @harvardmed]

The study found a dramatic reduction in medical errors resulting in harm or leading to patient death when first-year resident-physician work hours were limited https://t.co/5aghmaD4ec

[Jing Li @RichardJing4]

Very proud to present our work investigating the value of HIPEC in the neoadjuvant setting (NHIPEC) among patients with ovarian cancer. BJOG! 😍amazing😊

[JLGTD @JLGTD]

ASCCP committee opinion on HPV vaccine when treatment ie with LEEP https://t.co/Qe57ycfh5a

[BJS @BJSurgery]

In the January issue of BJS: Surgical knives: the scalpel https://t.co/jvEKesNTdj @bplwijn @des_winter @ksoreide @MalinASund @evanscolorectal @nfmkok @paulo_sutt @robhinchliffe1 @young_bjs

[European Network of Young Gynae Oncologists @ENYGO_official]

ENYGO prepared a special present for you. In this recent article we are covering the best orginal research presented for the first time during @ESGO_society 2022 Congress in Berlin. Enjoy! https://t.co/5eFUnrSNnS

[Ryan Kahn, MD, MHS @RyanKahnMD1]

Should we be using a new metric to counsel our patients with ovarian cancer on long-term survival?

Ten-year conditional probability of survival for patients with ovarian... https://t.co/zgrAWKYMR8 @SGO_org @IGCSociety @MSKCancerCenter

[EORTC Breast Cancer Group @EORTC_BCG]

Now out in @TheLancetOncol and soon at #SABCS22 the results of the overall survival IA of MonarchE: at 4 years, abemaciclib is associated with⬆️IDFS (6.4%difference, HR 0.66, p<.0001). Further follow-up is needed to det if benefit in OS (HR 0.93;p=0·50).
https://t.co/q3TY26RPq7

[@GynOncJnls @gynoncjnls]

#KELIM score may be a #marker of #chemosensitivity in patients with #ovarian #cancer treated with neoadjuvant chemotherapy 🇨🇦 @SabrinaPiedimo1 @Gyne_Oncology @SGO_org @IGCSociety @ESGO_society @ASCO @myESMO @OncoAlert @UHN https://t.co/pO7RsxFHaS

[@GynOncJnls @gynoncjnls]

BRCA1, BRCA2, RAD51C, and RAD51D mutations were associated with exceptional benefit from rucaparib in ovarian cancer @SGO_org @IGCSociety @ESGO_society @OncoAlert @ASCO @myESMO @Gyne_Oncology @GOG https://t.co/z3rLxUAzMV

[Boston Breast Surgeon @DrTedJames]

It's great to have more current data on managing phyllodes tumors. The historical 1cm margin requirement was excessive. This study found that only positive margins, not margin width, are related to recurrence.
https://t.co/D4Ih6DXWcE
#phyllodes
#breasttumors